A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs LOR 2040 (Primary) ; Capecitabine
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2013 Additional lead trial centre deleted as reported by ClinicalTrials.gov record.
- 14 Jun 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.